Table 2 Comparison of clinical and pathological data of patients with anti-GBM disease with and without serum anti-C1q antibodies
From: Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease
| Ā | Anti-C1q antibody positive (nā=ā15) | Anti-C1q antibody negative (nā=ā10) | P |
|---|---|---|---|
Age (years) | 34.0āĀ±ā16.0 | 28.5āĀ±ā9.8 | 0.342 |
Gender (male/female) | 13/2 | 9/1 | 1.000 |
Hydrocarbon exposure | 2/15 (13.3%) | 1/10 (10%) | 1.000 |
Prodromal infection | 5/15 (33.3%) | 5/10 (50%) | 0.678 |
Smoker | 6/15 (40%) | 5/10 (50%) | 1.000 |
Hemoptysis | 6/15 (40%) | 6/10 (60%) | 0.428 |
Oliguria/anuria | 8/15 (53.3%) | 6/10 (60%) | 1.000 |
Gross hematuria | 6/15 (40%) | 6/10 (60%) | 0.428 |
Nephrotic syndrome | 4/7 (57.1%) | 2/4 (50%) | 1.000 |
Serum creatinine (Ī¼mol/L) | 1016.2āĀ±ā340.0 | 954.1āĀ±ā384.7 | 0.675 |
Interval from onset (days) | 50.4āĀ±ā33.4 | 46.0āĀ±ā36.8 | 0.766 |
Level of anti-GBM antibodies (U/mL) | 88.2āĀ±ā49.0 | 89.2āĀ±ā36.9 | 0.957 |
ANCA positive | 2/15 (13.3%) | 0/10 (0) | 0.500 |
Hemoglobin (g/L) | 78.2āĀ±ā24.3 | 86.1āĀ±ā34.3 | 0.506 |
Percentage of crescents in glomeruli (%) | 100.0 (90.0-100.0) | 88.5 (80.8-100.0) | 0.210 |
āCellular crescents (%) | 85.5 (24.8-100.0) | 75.0 (29.5-83.3) | 0.462 |
āFibrocellular crescents (%) | 14.5 (0ā50.0) | 25.0 (16.8-68.0) | 0.360 |
āFibrotic crescents (%) | 0 (0ā2.3) | 0 | 0.443 |
Positive C1q deposit in the kidney | 4/15 (26.7%) | 3/10 (30%) | 1.000 |
Renal survival (1Ā year) | 1/15 (6.7%) | 1/10 (10%) | 1.000 |
Patient survival (1Ā year) | 10/15 (66.7%) | 8/10 (80%) | 0.659 |